Children with SMA Type 1 now have access to drug therapies that result in prolonged survival, enhanced motor milestones and better motor function. KAFOs make standing and walking easier by compensating for muscle weakness and improving joint alignment and stability. This study aims to describe KAFOs in drug treated children with SMA Type 1. This retrospective study collected data from the hospital electronic patient records system (EPIC) between July 2018 and March 2022 to include twelve out of forty-five children with SMA 1 (five males and seven females) receiving drug therapies, aged between 21-59 months at the time of KAFO casting. Age of child, movement range of lower limbs and level of function was collected within one month prior to KAFO casting. The median age of children wearing KAFOs was 36.5 months. At the time of casting for KAFOs, ten children were able to sit independently, and eleven children used a thoracic lumbar sacral orthosis (TLSO). All children were standing with support including orthoses such as AFOs and gaiters. Twelve children were using KAFOs to stand independently or with support, with one child walking using a Kaye walker. One child stopped using KAFOs due to contractures. Contractures of one or more joints in the legs were present in six children, with no reported data on three children. This study describes the clinical presentation of children with SMA Type 1 using KAFOs to aid standing and/or walking. There is currently no clear consensus on the prescription and use of KAFOs in the SMA Type 1 population. With the changing picture of children with SMA type 1 there is a need to understand how to best manage and promote functional skills. Further studies with a larger cohort describing the use of KAFOs in this population would be beneficial.